- Home
- PGY vs PRTA Comparison
PGY vs PRTA Comparison
Compare PGY & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- PRTA
- Stock Information
- Founded
- PGY 2016
- PRTA 2012
- Country
- PGY United States
- PRTA Ireland
- Employees
- PGY N/A
- PRTA N/A
- Industry
- PGY Finance: Consumer Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- PRTA Health Care
- Exchange
- PGY Nasdaq
- PRTA Nasdaq
- Market Cap
- PGY 863.7M
- PRTA 809.8M
- IPO Year
- PGY N/A
- PRTA N/A
- Fundamental
- Price
- PGY $16.44
- PRTA $4.59
- Analyst Decision
- PGY Strong Buy
- PRTA Buy
- Analyst Count
- PGY 9
- PRTA 9
- Target Price
- PGY $21.61
- PRTA $27.67
- AVG Volume (30 Days)
- PGY 2.6M
- PRTA 2.8M
- Earning Date
- PGY 05-07-2025
- PRTA 05-08-2025
- Dividend Yield
- PGY N/A
- PRTA N/A
- EPS Growth
- PGY N/A
- PRTA N/A
- EPS
- PGY N/A
- PRTA N/A
- Revenue
- PGY $1,076,961,000.00
- PRTA $137,935,000.00
- Revenue This Year
- PGY $19.84
- PRTA N/A
- Revenue Next Year
- PGY $13.99
- PRTA $122.59
- P/E Ratio
- PGY N/A
- PRTA N/A
- Revenue Growth
- PGY 23.69
- PRTA 54.55
- 52 Week Low
- PGY $8.20
- PRTA $4.32
- 52 Week High
- PGY $19.20
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- PGY 66.97
- PRTA 19.53
- Support Level
- PGY $13.85
- PRTA $4.32
- Resistance Level
- PGY $17.44
- PRTA $4.94
- Average True Range (ATR)
- PGY 0.80
- PRTA 0.52
- MACD
- PGY 0.18
- PRTA -0.15
- Stochastic Oscillator
- PGY 73.33
- PRTA 7.24
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).